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Fractures to the osteoporotic bone feature a delay in callus formation and reduced enchondral ossiﬁca-
tion. Human mesenchymal stem cells (hMSC), the cellular source of fracture healing, are recruited to
the fracture site by cytokines, such as BMP-2 and BMP-7. Aim of the study was to scrutinize hMSC for
osteoporosis associated alterations in BMP mediated migration and invasion as well as in extracellular
matrix (ECM) binding integrin expression.
HMSC were isolated from 18 healthy or osteoporotic donors. Migration was assessed using a collagen
IV coated micro-slide linear gradient chamber and time-lapse microscopy. Invasion was analyzed
utilizing an ECM coated transmembrane invasion assay. Quantitative real-time RT PCR was performed
for the ECM binding integrins a1, a2, a3, a4, a5, a11, av and b1.
HMSC from osteoporotic patients showed a signiﬁcant increase of migration upon BMP-2 or FCS stim-
ulation, as well as a signiﬁcant increase of invasion upon BMP-2, BMP-7 or FCS stimulation. Nevertheless,
the migration and invasion capacity was signiﬁcantly decreased compared to healthy controls. Out of all
integrins analyzed, collagen binding integrin a2 was signiﬁcantly downregulated in hMSC from
osteoporotic patients.
In conclusion, we here demonstrate for the ﬁrst time osteoporosis associated alterations in BMP
mediated hMSC recruitment. These ﬁndings may underlie the reduced healing of osteoporotic fractures.
Nevertheless, the maintained migration and invasion response upon BMP stimulation illustrates the
therapeutic potential of these clinically approved substances in the treatment of osteoporotic fractures.
Another therapeutic target may be the downregulation of the collagen binding integrin a2 in hMSC from
osteoporotic patients.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Fractures to the osteoporotic bone typically feature more
complex fracture patterns, reduced cancellous and cortical bone,
leading to an impaired stability of the osteosynthetic ﬁxation [1].
Furthermore, the fracture healing itself seems to be reduced [2].
Animal models revealed a delay in callus formation and enchondral
ossiﬁcation of the osteoporotic fracture [3,4]. Mesenchymal stemcells are the cellular sources of fracture healing. Upon stimulation
with cytokines and chemokines hMSC migrate to the fracture site,
where they proliferate and differentiate into osteogenic precursor
cells [5,6]. Recent studies on hMSC from osteoporotic patients
showed a signiﬁcantly reduced osteogenic differentiation capacity
[7–10]. Unfortunately, there are no studies investigating osteopo-
rosis associated alterations of the recruitment process prior to
differentiation. Recruitment of hMSC to the fracture site requires
active migration towards chemokines or cytokines and invasion
by proteolytic interaction with the extracellular matrix (ECM)
[11]. Some of the most potent chemoattractants belong to the
tumor necrosis factor (TNF) and the transforming growth
factor beta (TGF-beta) superfamilies [12,13]. As a member of the
TGF-beta family, bone morphogenetic protein (BMP)-2 and
BMP-7 are known to induce migration in hMSC [14,15]. BMP-2
and BMP-7 are both clinically approved for the treatment of
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seems to be mediated via activation of different integrins, such
as integrin a5 and b1 [18,19]. Preliminary data from our group
recently suggested a downregulation of the collagen binding
integrin a2 in hMSC from osteoporotic patients [20]. Studies in cell
lines featuring downregulation of integrin a2 revealed decreased
cellular adhesion and impaired migration on collagen I and IV,
whereas upregulation of integrin a2 lead to an increased migratory
activity [21,22].
Therefore, aim of the present study was to evaluate whether our
preliminary ﬁndings of integrin a2 downregulation in hMSC from
osteoporotic patients could be conﬁrmed in a larger patient cohort.
In addition, the expression of other relevant ECM binding integrins
should be analyzed. Furthermore, we intended to scrutinize hMSC
with regards to osteoporosis associated alterations in BMP-2 and
BMP-7 mediated migration and invasion. Such ﬁndings could con-
tribute to a deeper understanding of the impaired fracture healing
in osteoporotic patients and lead to new therapeutic approaches.
2. Materials and methods
2.1. Cells and cell culture
HMSC were isolated from femoral heads of patients undergoing
hip joint replacement due to a proximal femoral fracture as pub-
lished previously [7,23,24]. Inclusion criteria were female gender,
age >60 years and a T-Score of either >1.0 SD for the healthy con-
trol group or <2.5 SD for the osteoporosis group as measured by
bone mineral density (DXA). Furthermore, only patients who suf-
fered a fracture due to an adequate trauma were included in the
healthy control group. In the osteoporosis group patients were
included who suffered a fragility fracture due to a low impact
trauma. The study was approved by the LMU ethical commission
(No. 311-04) and performed according to the Declaration of
Helsinki.
The hMSC characteristics were veriﬁed according to Dominici
et al. [25]. In brief, hMSC were plastic adherent as well as proven
to be positive (>95%) for the hMSC-related markers CD105, CD90,
CD73 and negative (<2%) for the hematopoiesis and leucocytes
related markers CD45, CD34, CD19, CD14, HLA-DR using ﬂow
cytometry. Furthermore, cells were differentiable into osteoblasts,
adipocytes and chondroblasts under standard in vitro differentiat-
ing conditions [7].
2.2. Migration assay
The assessment of 2-D migration was carried out in linear gra-
dient micro slide chemotaxis chambers coated with collagen IV
(IBIDI, Germany) as published earlier [11]. In brief, cells were
seeded in a concentration of 1  106/ml along the cultivation chan-
nel and incubated for 3 h. Subsequently, culture medium was
washed out and replaced by serum free medium. Microslide
reservoirs were ﬁlled with serum free culture medium and the
chemoattractant gradient was applied. BMP-2 and BMP-7 (R&S
Systems, USA) were used in a concentration of 100 ng/ml and
FCS in a concentration of 10%. Serum free culture medium served
as a control. After 1 h stabilization and equilibration of the chemo-
taxis gradient time lapse analyses were performed over 15 h in a
controlled bio-chamber (Pecon, Germany) at 5% CO2 and 37 C.
Microscopy, cell tracking and data processing were carried out as
published earlier [11]. The migration towards the chemokine
gradient was quantiﬁed by calculating the forward migration index
(FMI). The FMI is the ratio of covered distance along the chemokine
gradient and the cell’s overall path length. At least three indepen-
dent experiments were performed for each donor. Aged matched
samples were analyzed in parallel.2.3. Invasion assay
3-D invasion was analyzed using a transwell invasion assay as
published earlier [11]. The invasion chamber cell culture inserts
(HTS FluoroBlok) were coated with 10 lg of human ECM (BD
Biosciences, USA). Cells (5  103) were seeded in 200 ll serum free
culture media into the upper compartment. The lower compart-
ment of the invasion chamber was ﬁlled with 600 ll serum free
culture media as control or one of the chemoattractant. BMP-2
and BMP-7 were used in a concentration of 30 ng/ml and FCS in
a concentration of 10%. After incubation, staining, large-ﬁeld
microscopy and cell counting were performed as published earlier.
Three independent experiments were carried out in triplicates for
each donor. Aged matched samples were analyzed in parallel.
2.4. Quantitative real-time RT-PCR
Total RNA was extracted with RNeasy Mini Kit (Qiagen). For
cDNA synthesis, 1 lg total RNA and AMV First-Strand cDNA Syn-
thesis Kit (Invitrogen) were used. For Quantitative RT-PCR Light-
Cycler Fast Start DNA Master SYBR Green kit (Roche, Munich,
Germany) and primer kits for Integrins a1, a2, a3, a4, a5, a11,
av and b1 as well as for glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) (Search-LC, Heidelberg, Germany) were used. The
PCR was performed in a LightCycler1.5 instrument (Roche)
equipped with LightCycler3.5.3 software. Crossing points for each
sample were determined by the second derivative maximum
method and relative quantiﬁcation was performed using the com-
parative DDCt method according to the manufacturer’s protocol.
The relative gene expression was calculated as a ratio to GAPDH
and data is given as fold changes compared to the healthy patients.
All PCR results have been reproduced minimum three times.
2.5. Statistical analysis
Statistical calculations were performed using GraphPad Prism
v5.02 (Graphpad Software Inc., USA). Signiﬁcance was ﬁxed at
p < 0.05 and tested by two-tailed unpaired t-test or one way
ANOVAwith Bonferroni corrections for multiple comparisons tests.
3. Results
3.1. Patient data
A total of 18 patients were included in our study. The mean age
of the healthy donors was 83 (±12 SD) years with a mean T-Score of
0.4 (±0.8 SD) at the lumbar spine and 0.7 (±0.2 SD) at the proximal
femur. The mean age of the osteoporotic donors was 82 (±7 SD)
years with a mean T-Score of 2.7 (±1.1 SD) and 3.0 (±0.6 SD)
at the spine and the proximal femur, respectively (Table 1).
3.2. Migration assay
2-D migration of hMSC was assessed over a period of 24 h uti-
lizing a collagen IV coated l-slide linear gradient chemotaxis
chamber. FCS is known to be a strong chemoattractant and served
as a positive control. HMSC from healthy donors revealed a FMI of
0.39 (±0.12 SD) towards the FCS gradient, while the FMI of hMSC
from osteoporotic patients was signiﬁcantly lower (0.24 (±0.08
SD)). The FMI of hMSC from healthy donors towards BMP-2 and
BMP-7 was 0.13 (±0.05 SD) and 0.09 (±0.08 SD), respectively. HMSC
from osteoporotic patients showed signiﬁcantly lower FMIs
towards both chemokines with a FMI of 0.06 (±0.04 SD) and 0.01
(±0.04 SD), respectively. Even though hMSC from osteoporotic
patients showed a signiﬁcantly lowered FMI, the 2-D migration




Age T-Score (SD) Age T-Score (SD)
Spine Femur Spine Femur
66 1.2 0.6 69 3.5 3.1
77 1.2 3.0
69 1.3 0.5 72 1.6 2.6
83 0.7 0.7 82 2.8 2.9
81 1.3 2.7
86 1.0 0.9 86 2.6 1.7
84 4.0 2.4
87 0.1 1.0 87 2.2 3.2
87 3.7 3.5
94 0.5 0.9 86 4.1 3.5
97 0.2 0.6 95 2.2 4.1
Mean 83 0.4 0.7 Mean 82 2.7 3.0
SD 12 0.8 0.2 SD 7 1.1 0.6
Fig. 1. 2-D migration assays on l-slide chemotaxis chambers upon BMP-2, BMP-7 or
patient. Migration towards the higher chemoattractant concentration is indicated by blac
graph of all donors showing mean values with standard deviation. HMSC from osteoporo
FCS compared to cells from healthy donors. Nevertheless, hMSC from osteoporotic pa
⁄ = p < 0.05. ⁄⁄ = p < 0.05 compared to respective control. (For interpretation of the refere
article.)
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stimulation HMSC from osteoporotic patients showed only very
low migratory response. In hMSC from healthy patients we found
a signiﬁcantly increase of 2D migration upon stimulation with all
three analyzed chemoattractants (Fig. 1).
3.3. Invasion assay
3-D invasion was analyzed using an ECM coated transwell
invasion assay. A mean number of 749 (±93 SD) cells from
healthy donors crossed the coated porous membrane upon FCS
stimulation. Upon BMP-2 or BMP-7 stimulation a mean number
of 316 (±81 SD) and 286 (±120 SD) was found in the lower com-
partment, respectively. HMSC from osteoporotic patients revealed
a signiﬁcantly lower invasion upon FCS stimulation, BMP-2 and
BMP-7 with 397 (±94 SD), 183 (±63 SD) and 145 (±37 SD) cells
crossing the coated membrane, respectively. Compared to the
negative control BMP-2, BMP-7 and FCS signiﬁcantly increased
3D invasion of hMSC from healthy and osteoporotic patients
(Fig. 2).FCS stimulation. (A) Representative scatter plots of a healthy and an osteoporotic
k cell paths, towards the lower concentration by red cell paths. (B) Grouped column
tic patients revealed a signiﬁcantly decreased migration towards BMP-2, BMP-7 and
tients showed a signiﬁcant increase of migration on BMP-2 and FCS stimulation.
nces to colour in this ﬁgure legend, the reader is referred to the web version of this
Fig. 2. 3-D invasion assay across an extracellular matrix barrier upon BMP-2, BMP-7 or FCS stimulation. (A) Representative ﬂuorescence stainings of hMSC from a healthy and
an osteoporotic donor on the lower side of the porous insert after 12 h of incubation with the chemoattractant. (B) Grouped column graph of all donors showing mean values
with standard deviation. Invasion towards BMP-2, BMP-7 and FCS is signiﬁcantly reduced in hMSC from osteoporotic patients compared to cells from healthy donors.
Bar = 1500 lm. ⁄ = p < 0.05. ⁄⁄ = p < 0.05 compared to respective control.
Fig. 3. Quantitative real-time RT-PCR of ECM binding integrins. Grouped column
graph of all donors showing mean values with standard deviation. HMSC from
osteoporotic patients revealed a signiﬁcant downregulation of integrin a2 in
comparison to hMSC from healthy donors. ⁄ = p < 0.05.
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In order to investigate a relationship between osteoporosis and
the expression of ECM binding integrins, we performed a quantita-
tive real-time RT PCR for the integrins a1, a2, a3, a4, a5, a11, av
and b1. Integrin expression of HMSC from healthy donors was set
to one. Compared to the healthy donors we found a 1.185
(±0.232 SD) fold upregulation for integrin a1, a 1.017 (±0.266 SD)
fold upregulation for integrin a3, a 0.87 (±0.076 SD) fold downreg-
ulation for integrin a5, a 1.004 (±0.236 SD) fold upregulation for
integrin a11, a 0.865 (±0.197 SD) fold downregulation for integrin
av and a 0.897 (±0.138 SD) fold downregulation for integrin b1.
Most strikingly, hMSC from osteoporotic patients revealed a signif-
icant 0.273 (±0.136 SD) fold downregulation of integrin a2 (Fig. 3).
4. Discussion
Aim of present study was to verify our hypothesis that hMSC
from osteoporotic patients feature a signiﬁcantly reduced
expression of the collagen binding integrins associated with an
impaired migration and invasion towards chemoattractants, such
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porotic patients were analyzed in an age matched manner. Prior to
inclusion all hMSC were characterized with regards to the minimal
criteria of the International Society for Cellular Therapy deﬁning
multipotent mesenchymal stem cells [25].
In order to assess migration of hMSC we performed time-lapse
analyses over a period of 24 h utilizing a two-dimensional (2-D)
collagen IV coated micro slide chemotaxis chamber. This elaborate
method is well established [11] allowing a precise migration anal-
yses on a single cell level with constant linear chemoattractant gra-
dients. We found a signiﬁcantly reduced migration activity of
hMSC from osteoporotic patients upon BMP-2 or BMP-7 stimula-
tion (Fig. 1). Apart from the migration upon stimulation with dis-
tinct chemoattractants involved in fracture healing, we could
detect a signiﬁcantly reduced migration upon stimulation with
FCS, a highly potent conglomerate of different chemoattractants.
Although on a reduced level, a signiﬁcant increase of migration
could still be induced by BMP-2 in hMSC from osteoporotic
patients. Comparing the effect of BMP-2 and BMP-7 on hMSC
migration, BMP-2 revealed to be a more potent stimulus in hMSC
from healthy donors and osteoporotic patients. These ﬁnding go
well in line with Mishima et al. who detected similar results in
human articular chondrocytes [26]. Among different BMPs ana-
lyzed, Lind et al. found BMP-2 to be the most potent chemoattrac-
tant for human osteoblasts [27].
HMSC invasion was analyzed using a three-dimensional (3-D)
transmembrane assays through an ECM barrier. Apart from migra-
tory activity, invasion requires additional cellular functions, such
as upregulation of other ECM binding receptors and synthesis of
proteolytic enzymes [11,28]. Similar to the ﬁndings in 2-D migra-
tion, the invasion analysis revealed a signiﬁcantly reduced invasion
capacity of hMSC from osteoporotic patients upon BMP-2, BMP-7
or FCS stimulation (Fig. 2). Nevertheless, all chemoattractants
analyzed still lead to a signiﬁcantly increased hMSC invasion com-
pared to the control group. The osteoporosis associated impair-
ment of hMSC migration and invasion upon BMP stimulation has
not been described in literature before. These ﬁndings may display
an osteoporosis associated limitation of hMSC recruitment to the
fracture site and may underlie the reduced fracture healing
described in osteoporotic animal models [3,4]. So far, studies on
osteoporosis associated alterations of hMSC to some extend disre-
garded the aspect of cellular recruitment and mainly focused on
osteogenic differentiation processes. HMSC from osteoporotic
patients have been shown to feature a decreased proliferative
capacity [8], the production of collagen I deﬁcient matrix [9], a
preferableness of adipogenic differentiation [29] and an impaired
osteogenic differentiation [10].
Despite the impairment of migration and invasion, we could
demonstrate a maintained cellular response upon BMP-2 or BMP-
7 stimulation in hMSC from osteoporotic patients. Similarly, Poun-
tos et al. observed an enhancement of proliferation and osteogenic
differentiation due to BMP-2 and BMP-7 in hMSC derived from
osteoporotic bone [30]. With regard to the BMP signal transduc-
tion, our group recently showed a reduced phosphorylation of
ERK1/2, but an accurate activation of SMAD1/5/8 [7].
The reduced migration and invasion activity may be due to a
differential expression of ECM binding integrins. Preliminary data
from our group suggested an osteoporosis associated downregula-
tion of collagen binding integrin a2 [20]. In the present study we
scrutinized hMSC from a larger cohort of healthy donors and oste-
oporotic patients with regards to expression of integrin a1, a2, a3,
a4, a5, a11, av and b1. Quantitative real-time RT-PCR could not
detect a signiﬁcantly alternated expression of integrins a1, a3,
a4, a5, a11, av and b1. As a major ﬁnding and in line with our
previous data, we could approve a signiﬁcant downregulation of
integrin a2 in hMSC derived from osteoporotic patients (Fig. 3).Studies utilizing different cell lines uncovered that migration on
collagen IV and laminin is largely mediated by integrin a2 and that
blocking of integrin a2 receptor signiﬁcantly inhibits migration
[22,31]. Apart from its important role in migration, integrin a2 is
involved in osteogenic differentiation of hMSC. Hu et al. showed
that integrin a2 activates ERK pathways by phosphorylation, thus
promoting the expression of osteogenic transcription factors, such
as Runx2. The authors could further demonstrate a dysregulation
of the a2/ERK/Runx2 pathway in hMSC derived from osteoporotic
patients [32]. This goes well in line with recently published data
from our group showing an impaired phosphorylation of ERK upon
BMP-2 stimulation. On the other hand, we further discovered an
accurate activation of the SMAD1/5/8 pathway upon BMP-2 stim-
ulation in hMSC from osteoporotic patients [7]. Both pathways,
ERK and SMAD, are known to be responsible for BMP signal trans-
duction [33,34]. Interestingly, Maegdefrau et al. revealed that
blocking of the SMAD pathway lead to a signiﬁcantly decreased
migration and invasion upon BMP stimulation [35]. Taking these
ﬁndings into account, the impairment of migration and invasion
found in hMSC from osteoporotic patients may be due to a down-
regulation of integrin a2 and reduced phosphorylation of ERK.
Nevertheless, migration and invasion can still be induced upon
BMP stimulation in hMSC from osteoporotic patients, presumably
via the maintained SMAD pathway.
In conclusion, we here demonstrate for the ﬁrst time a signiﬁ-
cantly reduced migration and invasion upon BMP-2 or BMP-7 stim-
ulation in hMSC derived from osteoporotic patients. These ﬁndings
may underlie the reduced healing of osteoporotic fractures. Never-
theless, the maintained migration and invasion response upon
BMP stimulation illustrates the therapeutic potential of these clin-
ically approved substances in the treatment of osteoporotic frac-
tures. Another therapeutic target may be the downregulation of
the collagen binding integrin a2 or its mediated signaling in hMSC
derived from osteoporotic patients.
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